Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Update

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) saw a large growth in short interest in November. As of November 15th, there was short interest totalling 18,930,000 shares, a growth of 7.0% from the October 31st total of 17,690,000 shares. Based on an average daily volume of 747,500 shares, the short-interest ratio is currently 25.3 days.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ KPTI opened at $0.81 on Wednesday. The company’s 50-day moving average is $0.84 and its 200 day moving average is $0.87. The stock has a market capitalization of $101.51 million, a P/E ratio of -0.71 and a beta of 0.05. Karyopharm Therapeutics has a 1 year low of $0.62 and a 1 year high of $1.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. The company had revenue of $38.78 million for the quarter, compared to analysts’ expectations of $37.86 million. During the same quarter in the previous year, the firm posted ($0.30) EPS. Research analysts anticipate that Karyopharm Therapeutics will post -0.94 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. StockNews.com cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Robert W. Baird reduced their price target on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Piper Sandler lifted their price target on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 6th. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Karyopharm Therapeutics in a report on Friday, November 1st. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $3.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Hedge Funds Weigh In On Karyopharm Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Point72 DIFC Ltd bought a new stake in Karyopharm Therapeutics in the 2nd quarter worth approximately $31,000. Geode Capital Management LLC lifted its stake in shares of Karyopharm Therapeutics by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company’s stock valued at $1,125,000 after buying an additional 43,856 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Karyopharm Therapeutics by 34.9% in the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock worth $182,000 after acquiring an additional 56,613 shares during the period. FMR LLC grew its stake in Karyopharm Therapeutics by 26.1% during the third quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after acquiring an additional 76,510 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Karyopharm Therapeutics in the 2nd quarter worth approximately $143,000. 66.44% of the stock is owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).